Top

Published in:

01-12-2007

The late phase of preconditioning and its natural clinical application—gene therapy

Authors: Roberto Bolli, Qian-Hong Li, Xian-Liang Tang, Yiru Guo, Yu-Ting Xuan, Gregg Rokosh, Buddhadeb Dawn

Published in: Heart Failure Reviews | Issue 3-4/2007

Abstract

There is little doubt that the discovery of ischemic preconditioning (PC) has been one of the fundamental milestones in the field of ischemic biology in the past 20 years. The purpose of this article is to review the pathophysiology and molecular basis of the late phase of myocardial PC. The exploitation of late PC for the development of novel gene therapy strategies aimed at inducing a permanently preconditioned cardiac phenotype (prophylactic cardioprotection) will also be discussed. Deciphering the mechanism of late PC has not only conceptual interest but also a considerable therapeutic implications, since transfer of the genes that underlie late PC would be expected to replicate the salubrious effects of this response of the heart to stress.

Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136PubMed

Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA (2004) Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95:125–134PubMedCrossRef

Bolli R (2000) The late phase of preconditioning. Circ Res 87:972–983PubMed

Yellon DM, Downey JM (2003) Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83:1113–1151PubMed

Guo Y, Wu WJ, Zhu XP, Li Q, Tang XL, Bolli R (2001) Exercise-induced late preconditioning is triggered by generation of nitric oxide. J Mol Cell Cardiol 33:A41 (Abstr.)

Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M (1993) Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 72:1293–1299PubMed

Marber MS, Latchman DS, Walker JM, Yellon DM (1993) Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88:1264–1272PubMed

Bolli R, Manchikalapudi S, Tang XL, Takano H, Qiu Y, Guo Y, Zhang Q, Jadoon AK (1997) The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res 81:1094–1107PubMed

Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 96:11507–11512PubMedCrossRef

10.

Bolli R, Dawn B, Tang XL, Qiu Y, Ping P, Xuan YT, Jones WK, Takano H, Guo Y, Zhang J (1998) The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol 93:325–338PubMedCrossRef

11.

Bolli R (2001) Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33:1897–1918PubMedCrossRef

12.

Jones SP, Bolli R (2006) The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40:16–23PubMedCrossRef

13.

Wang Y, Guo Y, Zhang SX, Wu WJ, Wang J, Bao W, Bolli R (2002) Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol 34:5–15PubMedCrossRef

14.

Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B (2002) Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55:506–519PubMedCrossRef

15.

Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R (2000) Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97:10197–10202PubMedCrossRef

16.

Shinmura K, Bolli R (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors. Ann Intern Med 143:615–618

17.

Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, Bolli R (2002) Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90:602–608PubMedCrossRef

18.

Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B, Bolli R (2003) Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 35:525–537PubMedCrossRef

19.

Kim SF, Huri DA, Snyder SH (2005) Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310:1966–1970PubMedCrossRef

20.

Ueda Y, Kitakaze M, Komamura K, Minamino T, Asanuma H, Sato H, Kuzuya T, Takeda H, Hori M (1999) Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 34:2120–2125PubMedCrossRef

21.

Tang XL, Takano H, Xuan YT, Sato H, Kodani E, Dawn B, Zhu Y, Shirk G, Wu WJ, Bolli R (2005) Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits. Circulation 112:2149–2156PubMedCrossRef

22.

Tang XL, Stein AB, Shirk G, Bolli R (2004) Hypercholesterolemia blunts NO donor-induced late preconditioning against myocardial infarction in conscious rabbits. Basic Res Cardiol 99:395–403PubMedCrossRef

23.

Kremastinos DT, Bofilis E, Karavolias GK, Papalois A, Kaklamanis L, Iliodromitis EK (2000) Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits. Atherosclerosis 150:81–89PubMedCrossRef

24.

Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM (2005) Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54:2360–2364PubMedCrossRef

25.

Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A (2004) Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47:1716–1721PubMedCrossRef

26.

del Valle HF, Lascano EC, Negroni JA, Crottogini AJ (2003) Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction. Mol Cell Biochem 249:21–30PubMedCrossRef

27.

Fenton RA, Dickson EW, Meyer TE, Dobson JG Jr (2000) Aging reduces the cardioprotective effect of ischemic preconditioning in the rat heart. J Mol Cell Cardiol 32:1371–1375PubMedCrossRef

28.

Abete P, Ferrara N, Cioppa A, Ferrara P, Bianco S, Calabrese C, Cacciatore F, Longobardi G, Rengo F (1996) Preconditioning does not prevent postischemic dysfunction in aging heart. J Am Coll Cardiol 27:1777–1786PubMedCrossRef

29.

Boengler K, Konietzka I, Buechert A, Heinen Y, Garcia-Dorado D, Heusch G, Schulz R (2006) Loss of ischemic preconditioning’s cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol (in press)

30.

Przyklenk K, Li G, Whittaker P (2001) No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. J Am Coll Cardiol 38:1741–1747PubMedCrossRef

31.

Wu WJ, Xuan YT, Tan W, Zhu X, Zhu Y, Guo Y (2003) The loss of ischemic preconditioning in the senescent heart is associated with impaired upregulation of inducible nitric oxide synthase and cyclooxygenase-2. Circulation 108:IV–187 (Abstr.)

32.

Shinmura K, Nagai M, Tamaki K, Bolli R (2004) Gender and aging do not impair opioid-induced late preconditioning in rats. Basic Res Cardiol 99:46–55PubMedCrossRef

33.

Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD, Wu WJ, Zhu Y, Bolli R (2003) Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 92:741–748PubMedCrossRef

34.

Li Q, Guo Y, Tan W, Stein AB, Dawn B, Wu WJ, Zhu X, Lu X, Xu X, Siddiqui T, Tiwari S, Bolli R (2006) Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol 290:H584–H589PubMedCrossRef

35.

Guo Y, Luo C, Dawn B, Tan W, Wu WJ, Hunt G, Zhu X, Li Q (2004) The cardioprotection afforded by iNOS gene therapy is mediated by COX-2 via an NF-kappaB-dependent pathway. Circulation 110:III–29 (Abstr.)

36.

Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qiu Y, Li JJ, Bolli R (1999) Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84:1095–1109PubMed

37.

Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclo-oxygenase-2 gene. Biochem J 302 (Pt 3):723–727PubMed

38.

Dawn B, Xuan YT, Marian M, Flaherty MP, Murphree SS, Smith TL, Bolli R, Jones WK (2001) Cardiac-specific abrogation of NF- kappa B activation in mice by transdominant expression of a mutant I kappa B alpha. J Mol Cell Cardiol 33:161–173PubMedCrossRef

39.

Verma IM, Weitzman MD (2005) Gene therapy: twenty-first century medicine. Annu Rev Biochem 74:711–738PubMedCrossRef

40.

Li Q, Guo Y, Luo C, Tan W, Wu WJ, Xu B, Siddiqui T, Rokosh GD, Bolli R (2004) Long-term protection against myocardial infarction with cyclooxygenase-2 (COX-2) gene therapy via a recombinant adeno-associated viral (rAAV) vector. Circulation 110:III–107 (Abstr.)

Title: The late phase of preconditioning and its natural clinical application—gene therapy
Authors: Roberto Bolli
Qian-Hong Li
Xian-Liang Tang
Yiru Guo
Yu-Ting Xuan
Gregg Rokosh
Buddhadeb Dawn
Publication date: 01-12-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Heart Failure Reviews / Issue 3-4/2007
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-007-9031-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

The late phase of preconditioning and its natural clinical application—gene therapy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2007

Cardioprotective actions of peptide hormones in myocardial ischemia

Postconditioning: a mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion

Postconditioning in man

Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection

Cardioprotection in stunned and hibernating myocardium

Connexin 43 in ischemic pre- and postconditioning

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page